Who are CSL Influenza Vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Flublok™ Quadrivalent by Sanofi, Inc., Hualan TIV, Trivalent split Inf, High-Dose Influenza Vaccine, Vaxigrip®, ccIIV4.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/csl-influenza-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

CSL Influenza Vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CSL Influenza Vaccine (CSL Influenza Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: inactivated influenza vaccine. Area: Immunology.

marketed inactivated influenza vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

CSL Influenza Vaccine (CSL Influenza Vaccine) — Seqirus. This inactivated influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CSL Influenza Vaccine TARGET	CSL Influenza Vaccine	Seqirus	marketed	inactivated influenza vaccine
Flublok™ Quadrivalent by Sanofi, Inc.	Flublok™ Quadrivalent by Sanofi, Inc.	Centers for Disease Control and Prevention	marketed	Recombinant inactivated influenza vaccine	Influenza hemagglutinin (HA) protein
Hualan TIV	Hualan TIV	Sanofi	marketed	Inactivated influenza vaccine
Trivalent split Inf	Trivalent split Inf	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Inactivated influenza vaccine
High-Dose Influenza Vaccine	High-Dose Influenza Vaccine	Saad Jamshed MD	marketed	Inactivated influenza vaccine
Vaxigrip®	Vaxigrip®	National University Hospital, Singapore	marketed	Inactivated influenza vaccine
ccIIV4	ccIIV4	Vanderbilt University Medical Center	marketed	Inactivated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (inactivated influenza vaccine class)

Seqirus · 3 drugs in this class
Center for Disease Prevention and Control of Beijing Military Region · 2 drugs in this class
Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
Sinovac Biotech Co., Ltd · 2 drugs in this class
La Jolla Institute for Immunology · 1 drug in this class
Mount Sinai Hospital, Canada · 1 drug in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
University of Sao Paulo · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
University of Witwatersrand, South Africa · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CSL Influenza Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/csl-influenza-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab